5-(2-Butyl-7-methoxy-1-benzofuran-4-yl)-1,3-diazinan-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-(2-Butyl-7-methoxy-1-benzofuran-4-yl)-1,3-diazinan-2-one
• 化学式: C₁₇H₂₂N₂O₃
• 分子量: 302.37
• InChiKey: GDFRFJZABVCREK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  63.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT
  申请人：De Jonghe Steven Cesar Alfons

  公开号：US20090036430A1

  公开（公告）日：2009-02-05

  This invention relates to substituted pyrido(3,2-d)pyrimidine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These derivatives are also useful in preventing or treating cardiovascular disorders, disorders of the central nervous system, TNF-α related disorders, viral diseases (including hepatitis C), erectile dysfunction and cell proliferative disorders.

  本发明涉及取代的吡啶并(3,2-d)嘧啶衍生物、它们的药学上可接受的盐、N-氧化物、溶剂化合物、前药和对映体，具有意外的理想药理特性，特别是高度活性的免疫抑制剂，因此在移植排斥和/或治疗某些炎症性疾病方面非常有用。这些衍生物还可用于预防或治疗心血管疾病、中枢神经系统疾病、TNF-α相关疾病、病毒性疾病（包括丙型肝炎）、勃起功能障碍和细胞增殖性疾病。
• Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
  申请人：——

  公开号：US20020004498A1

  公开（公告）日：2002-01-10

  A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. Pharmaceutical formulations and kits are provided as well.

  提供了一种治疗哺乳动物男性个体勃起功能障碍的方法。该方法包括在有效给药方案的范围内，经粘膜给药磷酸二酯酶抑制剂或其药学上可接受的盐、酯、酰胺或衍生物。首选的给药方式包括经口腔、舌下和经直肠途径。此外，还提供药物制剂和试剂盒。
• Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
  申请人：——

  公开号：US20020037828A1

  公开（公告）日：2002-03-28

  A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as “as needed” basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.

  提供了一种通过施用磷酸二酯酶抑制剂（例如，III型、IV型或V型磷酸二酯酶抑制剂）治疗早泄的方法。在一个优选的实施方案中，根据 "需要 "给药，即在性活动前立即或数小时给药。此外，还提供药物制剂和包装套件。
• Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction
  申请人：——

  公开号：US20030134861A1

  公开（公告）日：2003-07-17

  A pharmaceutical formulation is provided for treating erectile dysfunction in a mammalian male individual. The pharmaceutical formulation includes a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, that is administered transmucosally within the context of an effective dosing regimen. Preferred modes of administration include transbuccal, sublingual and transrectal routes. A kit for the administration of the pharmaceutical formulation is also provided.

  提供了一种治疗哺乳动物男性个体勃起功能障碍的药物制剂。该药物制剂包括一种磷酸二酯酶抑制剂或其药学上可接受的盐、酯、酰胺或衍生物，在有效给药方案内经粘膜给药。优选的给药方式包括经口腔、舌下和经直肠途径。此外，还提供了一种用于施用药物制剂的试剂盒。
• Treatment of female sexual dysfunction with phosphodiesterase inhibitors
  申请人：——

  公开号：US20040014761A1

  公开（公告）日：2004-01-22

  A topical pharmaceutical composition is provided for the treatment of female sexual dysfunction, wherein the composition is formulated so as to contain a therapeutically effective amount of a phosphodiesterase inhibitor and a pharmaceutically acceptable carrier for topical administration. The phosphodiesterase inhibitor is generally selected from Type III, Type IV, Type V, and nonspecific phosphodiesterase inhibitors.

  提供了一种用于治疗女性性功能障碍的外用药物组合物，其中该组合物经配制后含有治疗有效量的磷酸二酯酶抑制剂和用于局部给药的药学上可接受的载体。磷酸二酯酶抑制剂一般选自 III 型、IV 型、V 型和非特异性磷酸二酯酶抑制剂。